Stocks breaking to new annual highs
S&P 500 oversold value screener
Relative strength momentum leaders
Upcoming earnings dates & reports
Filter and sort all 500 stocks
Continuous multi-factor scoring & catalyst forensics
Today's biggest gainers and losers
Humana is the fourth-largest Medicare Advantage (MA) insurer in the U.S., with approximately 5.7 million MA members representing ~75% of total revenue. The company operates integrated care delivery through CenterWell primary care clinics (370+ locations) and home health services, creating a vertically integrated model that differentiates it from pure-play insurers. Stock performance is highly sensitive to CMS Star Ratings (affecting bonus payments), medical loss ratios (MLR), and Medicare Advantage bid dynamics.
Humana receives fixed monthly capitation payments from CMS for each Medicare Advantage enrollee, with bonus payments (3-5% premium lift) tied to 4-Star or higher quality ratings. The company profits by managing medical costs below capitation rates - targeting MLRs of 85-87% while investing in preventive care through owned primary care clinics and home health services. Vertical integration through CenterWell (370+ clinics serving 300K+ patients) enables better care coordination, reduced hospitalizations, and improved risk adjustment coding that increases per-member payments. The company's scale in MA (5.7M members) provides negotiating leverage with providers and spreads fixed administrative costs across a large base. Profitability hinges on accurate actuarial pricing during annual CMS bid submissions, effective utilization management, and maintaining Star Ratings above 4.0 to capture bonus revenue.
CMS Star Ratings announcements (October) - 4.0+ rating drives 3-5% revenue premium per member
Medical Loss Ratio trends and guidance - every 100bps MLR change impacts margins by ~$1.3B annually
Medicare Advantage membership growth/retention - particularly individual MA enrollment during Annual Enrollment Period (Oct-Dec)
CMS rate notices (April) - final payment rates for following year, typically 3-4% base increases
Quarterly earnings surprises driven by utilization patterns - inpatient admissions, ER visits, elective procedures
Regulatory changes to risk adjustment methodology or MA payment benchmarks
CMS policy risk - potential Medicare Advantage payment cuts, risk adjustment model changes, or 'Medicare for All' proposals that could eliminate private MA plans
Star Ratings volatility - algorithmic changes to quality metrics can cause sudden rating drops (Humana experienced downgrades affecting 1.4M members in recent cycles), eliminating 3-5% bonus revenue
Aging provider networks and primary care physician shortages limiting ability to expand integrated care model in key geographies
UnitedHealth's Optum vertical integration advantage - larger scale in care delivery (60K+ employed/affiliated physicians vs. Humana's smaller CenterWell footprint)
CVS-Aetna combination leveraging retail pharmacy touchpoints for MA member acquisition and engagement
Regional Blues plans and Kaiser Permanente maintaining strong local market positions with established provider relationships
Reserve development risk - adverse claims development could require $500M-1B+ reserve strengthening if utilization trends worsen
Debt refinancing exposure - $9.8B debt with portions maturing 2025-2030 facing higher refinancing rates in current environment
Regulatory capital requirements - state insurance regulators mandate minimum Risk-Based Capital (RBC) ratios, limiting dividend/buyback flexibility during earnings volatility
low - Medicare revenue is government-funded and non-discretionary, insulating the business from GDP fluctuations. However, Medicaid enrollment (smaller segment) expands during recessions as unemployment rises. Utilization patterns show modest correlation to economic conditions - seniors may defer elective procedures during downturns, temporarily improving MLR, but pent-up demand eventually normalizes. The 65+ demographic growth (10,000 daily aging into Medicare) provides structural tailwind independent of economic cycles.
Moderate sensitivity through investment portfolio (primarily fixed-income securities backing reserves). Rising rates increase investment income on $15-20B portfolio, adding 10-15 cents EPS per 100bps rate increase. However, higher rates compress valuation multiples for healthcare stocks and increase borrowing costs on $9.8B debt (70% debt/equity). The company's low P/E multiple (currently 0.2x P/S, 10.4x EV/EBITDA) reflects limited growth expectations, making it less rate-sensitive than high-multiple growth stocks.
Minimal direct credit exposure - revenue is primarily government-sourced (CMS payments) with minimal counterparty risk. Provider payment obligations are contractual but spread across thousands of hospitals/physicians. Balance sheet shows strong liquidity (2.0x current ratio) and moderate leverage (0.70 debt/equity). Primary financial risk is reserve adequacy for incurred-but-not-reported (IBNR) claims, not credit defaults.
value - Trading at 0.2x P/S and 10.4x EV/EBITDA with 1.7% FCF yield despite $130B revenue scale. Recent 28% one-year decline and 35% six-month drop reflect Star Ratings concerns and MLR pressure, creating contrarian opportunity for investors betting on operational turnaround. Low 6.6% ROE and compressed margins (2.1% operating, 0.9% net) signal distressed valuation. Attracts deep value investors focused on mean reversion in MA profitability and potential private equity interest given integrated care assets.
high - Stock exhibits elevated volatility around CMS announcements (Star Ratings in October, rate notices in April) and quarterly earnings due to binary MLR outcomes. Recent 23% three-month decline demonstrates sensitivity to guidance revisions. Healthcare policy headlines (Medicare reform debates) create additional volatility. Beta likely 1.2-1.5x given operational leverage to medical cost trends and regulatory exposure.
